Secondary Loss of Response to an Infliximab Biosimilar with Anti-Drug Antibodies
A 52-year-old man with ileocolonic Crohn's disease has been receiving an infliximab biosimilar at 5 mg/kg every 8 weeks for 14 months. He initially had a clinical response and a normal C-reactive protein. Over the past 8 weeks he has developed increased stool frequency, urgency, and abdominal pain. C-reactive protein is 18 mg/L and fecal calprotectin is 450 µg/g. A serum trough level before the next infusion is 0.8 µg/mL, and anti-drug antibodies are 120 ng/mL. He has had no infusion reactions. Albumin is 3.2 g/dL. The product has been stored in the clinic refrigerator and reconstituted according to the label. The gastroenterology team is considering whether to shorten the interval, increase the dose, or switch to another agent, and asks what product-handling factors could have contributed to immunogenicity.
1. Interpret the trough level and anti-drug antibodies in this patient.
Read the worked answer
The trough of 0.8 µg/mL is below the usual target range of roughly 3 to 7 µg/mL for Crohn's disease, and the positive anti-drug antibodies at 120 ng/mL indicate immunogenic failure. The pattern is not simply underexposure from a fixed interval; the antibodies are likely increasing clearance and neutralizing drug activity. The rise in CRP and calprotectin supports active inflammation rather than irritable bowel symptoms. Low albumin can increase infliximab clearance and is a marker of higher inflammatory burden. Before changing therapy, confirm adherence, check for infection or other causes of symptoms, and ensure the sample was drawn at the correct trough time. The combination of low trough plus positive antibodies makes dose intensification less predictable than switching to a drug with a different target or using an immunomodulator, depending on disease severity and prior therapies.
2. Compare dose intensification with switching therapy, and state what additional information would guide the choice.
Read the worked answer
Dose intensification - increasing to 10 mg/kg or shortening the interval to every 4 to 6 weeks - can overcome low trough in some patients, but with high anti-drug antibodies it may transiently increase drug exposure while stimulating more antibody formation. It is most reasonable when symptoms are mild, antibodies are low, and the patient has limited alternatives. Switching to a different mechanism, such as an anti-integrin or anti-interleukin agent, avoids the immunogenic target; switching to another anti-TNF agent is an option but may be less effective if antibodies are cross-reactive. Adding an immunomodulator can reduce immunogenicity but adds infection and malignancy risks. The choice should consider disease severity, prior biologic exposure, fistula or stricturing disease, infection risk, and patient preference. Objective reassessment with imaging or colonoscopy may be needed if symptoms are disproportionate to inflammatory markers.
3. Which biopharmaceutic and handling factors could contribute to immunogenicity of a biosimilar monoclonal antibody?
Read the worked answer
Immunogenicity can arise from product-related aggregates, particles, or impurities; from improper cold-chain storage; from shaking or vigorous agitation that denatures protein; from freeze-thaw cycles; from incorrect reconstitution volume or diluent; and from prolonged storage after reconstitution. Silicone oil from syringes and container surfaces can also promote aggregation. The clinic should audit refrigerator temperature logs, transport records, and preparation practices. Even with correct handling, patient factors such as low albumin, high inflammatory burden, and genetic immune response contribute. The presence of anti-drug antibodies does not by itself prove a product defect, but a cluster of early antibody formation in multiple patients should trigger a batch and handling investigation.